{
  "docId": "019de073-8606-762c-9e2e-06d280bc8199",
  "docSlug": "fe3546a131d6b03dbc05b580d2cda1c4",
  "documentTitle": "CTI BioPharma | Investor Presentation Deck | 24 slides",
  "authorId": "cti-biopharma",
  "authorName": "CTI BioPharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 23,
  "pageCount": 24,
  "prevPage": 22,
  "nextPage": 24,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide uses a three-column layout to summarize key business pillars.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-8606-762c-9e2e-06d280bc8199/23",
  "deckHref": "/decks/019de073-8606-762c-9e2e-06d280bc8199",
  "deckJsonHref": "/decks/019de073-8606-762c-9e2e-06d280bc8199.json",
  "deckAnchorHref": "/decks/019de073-8606-762c-9e2e-06d280bc8199#slide-23",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.18
      },
      "kind": "callout",
      "text": "VONJO: Potential Best in Class Therapy for Cytopenic Myelofibrosis",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "21ae4ce0-6de3-452e-b8df-71724bb63536",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.85,
        "x": 0.08,
        "y": 0.45
      },
      "kind": "list",
      "text": "VONJO Now Approved; Strong Financial Position; Well Defined Market",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "19338959-a8ce-47c7-a900-ee3858b8834a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.2,
        "x": 0.36,
        "y": 0.62
      },
      "kind": "metric",
      "text": "$95.9 M cash at end of 2Q22",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "681f0836-746a-49ac-8ac2-00d5cb53733e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.24,
        "y": 0.88
      },
      "kind": "paragraph",
      "text": "VONJO is a kinase inhibitor indicated for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 x 10^9/L.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e5f2cf52-a792-4117-b39f-66e5fd976707",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.05,
        "y": 0.04
      },
      "kind": "title",
      "text": "CTI: Ready for Successful Commercialization",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a661d44e-e57d-4176-be01-4bc961b33a07",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}